Centessa Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:CNTA)

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) was the target of unusually large options trading activity on Wednesday. Traders acquired 10,659 put options on the company. This is an increase of 1,668% compared to the average daily volume of 603 put options.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA traded down $0.03 during trading on Wednesday, reaching $39.70. 8,399,772 shares of the company traded hands, compared to its average volume of 2,286,323. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a 52 week low of $9.60 and a 52 week high of $40.26. The firm has a market capitalization of $5.80 billion, a PE ratio of -21.69 and a beta of 1.55. The company’s 50 day moving average is $26.29 and its two-hundred day moving average is $25.24.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, March 31st. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.10). As a group, sell-side analysts predict that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Oppenheimer raised their target price on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. Stephens downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Truist Financial upped their target price on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, January 29th. Needham & Company LLC downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Chardan Capital reiterated a “buy” rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, January 2nd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $40.00.

Insider Activity

In other news, insider Gregory M. Weinhoff sold 73,196 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the transaction, the insider owned 65,925 shares in the company, valued at $1,735,805.25. The trade was a 52.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Iqbal J. Hussain sold 38,951 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the sale, the insider directly owned 57,645 shares of the company’s stock, valued at approximately $1,449,771.75. The trade was a 40.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 349,073 shares of company stock valued at $9,429,412 in the last 90 days. 7.09% of the stock is owned by company insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd bought a new stake in Centessa Pharmaceuticals during the 4th quarter worth approximately $80,000. T. Rowe Price Investment Management Inc. raised its stake in shares of Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after acquiring an additional 1,516 shares during the last quarter. Coastal Bridge Advisors LLC lifted its holdings in shares of Centessa Pharmaceuticals by 7.1% during the fourth quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock worth $351,000 after purchasing an additional 931 shares during the period. XTX Topco Ltd acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter worth $1,978,000. Finally, Voloridge Investment Management LLC bought a new stake in shares of Centessa Pharmaceuticals in the fourth quarter worth $8,710,000. Institutional investors own 82.01% of the company’s stock.

Key Centessa Pharmaceuticals News

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Lilly agrees to acquire Centessa for up to $7.8 billion — $38 in cash per share plus a contingent value right (CVR) for additional milestones, bringing Centessa’s pipeline (notably OX2R agonists for sleep/wake disorders) into Lilly’s neuroscience franchise. This is the primary catalyst lifting CNTA shares. Eli Lilly to acquire Centessa in $6.3B deal
• Neutral Sentiment: Unusual options flow — recent spikes in both calls and puts (large put block of 10,659 contracts reported) signal significant hedging/speculation and likely higher intraday volatility as arbitrageurs and speculators position around the deal and CVR outcome.
• Negative Sentiment: Shareholder law firms have launched investigations and issued alerts questioning whether the $38 cash + CVR structure reflects a fair process and price for public shareholders, raising the prospect of litigation or delay. Investor Alert — Kahn Swick & Foti
• Negative Sentiment: Multiple analyst downgrades (Needham, Wolfe Research, Stephens moved ratings toward Hold) reduce near‑term buy-side support and reflect concerns over deal dynamics/valuation and near-term upside beyond the offer. Needham downgrade
• Negative Sentiment: Recent quarter missed EPS expectations (reported $(0.48) vs. consensus $(0.38)), underscoring execution/financial risks if the deal faces delay or renegotiation. Earnings release / MarketBeat

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.